Application of EMBM to Structure-Based Design of Warheads for Protease Inhibitors

被引:0
|
作者
Traube, Tamar [1 ]
Shokhen, Michael [1 ]
Albeck, Amnon [1 ]
机构
[1] Bar Ilan Univ, Dept Chem, Julius Spokojny Bioorgan Chem Lab, IL-52900 Ramat Gan, Israel
关键词
Enzyme inhibitors; Proteases; Quantitative structure-activity relationship; Structure-based drug design; Transition-state analog; ACID AMIDE HYDROLASE; FAAH INHIBITORS; ACTIVE-SITE; DRUG DESIGN; CATHEPSIN-K; SERINE; POTENT; DISCOVERY; THROMBIN;
D O I
10.1002/minf.201300099
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Most CADD tools handle non-covalent enzyme inhibitors, despite the growing interest of the pharma industry in covalent inhibitors. We have recently introduced an enzyme mechanism-based method, EMBM, as a computational tool for binding trend analysis and prediction of chemical sites (CS) of reversible covalent enzyme inhibitors. In the current study we demonstrate the utility of EMBM to structure-based applications. In this mode, the energy of the enzyme-inhibitor covalent bond is accounted for by the W1 and W2 covalent descriptors we have developed, whereas the non-covalent interactions between the inhibitor CS and the enzyme active site can be estimated directly on the 3D structure of the enzyme-inhibitor complex.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [1] Structure-based design of parasitic protease inhibitors
    Li, RS
    Chen, XW
    Gong, BQ
    Selzer, PM
    Li, Z
    Davidson, E
    Kurzban, G
    Miller, RE
    Nuzum, EO
    McKerrow, JH
    Fletterick, RJ
    Gillmor, SA
    Craik, CS
    Kuntz, ID
    Cohen, FE
    Kenyon, GL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 1996, 4 (09) : 1421 - 1427
  • [2] STRUCTURE-BASED DESIGN OF ASPARTYL PROTEASE INHIBITORS
    THAISRIVONGS, S
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 20 - CINF
  • [3] Structure-based design and synthesis of aspartyl protease inhibitors
    Ghosh, AK
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2642 - U2642
  • [4] Structure-based drug design of HIV protease inhibitors.
    Navia, MA
    Tung, RD
    Chaturvedi, PR
    Rao, BG
    Partaledis, JA
    Kim, EE
    [J]. FASEB JOURNAL, 1996, 10 (06): : 2436 - 2436
  • [5] STRUCTURE-BASED DESIGN OF NOVEL NONPEPTIDIC HIV PROTEASE INHIBITORS
    LOVASZ, KD
    MORRIS, JK
    TOMICH, PK
    WATENPAUGH, KD
    HOWE, WJ
    DOLAK, LA
    ROMINES, KR
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 25 - MEDI
  • [6] Structure-based design and optimization of potent inhibitors of the adenoviral protease
    Grosche, Philipp
    Sirockin, Finton
    Mac Sweeney, Aengus
    Ramage, Paul
    Erbel, Paul
    Melkko, Samu
    Bernardi, Anna
    Hughes, Nicola
    Ellis, David
    Combrink, Keith D.
    Jarousse, Nadine
    Altmann, Eva
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 438 - 443
  • [7] Structure-based thermodynamic design of peptide ligands:: Application to peptide inhibitors of the aspartic protease endothiapepsin
    Luque, I
    Gömez, J
    Semo, N
    Freire, E
    [J]. PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1998, 30 (01): : 74 - 85
  • [8] Structure-based design of non-peptide HIV protease inhibitors
    Ghosh, AK
    Shin, D
    Swanson, L
    Krishnan, K
    Cho, H
    Hussain, KA
    Walters, DE
    Holland, L
    Buthod, J
    [J]. FARMACO, 2001, 56 (1-2): : 29 - 32
  • [9] STRUCTURE-BASED DESIGN OF SYMMETRICAL INHIBITORS OF HIV-1 PROTEASE
    ERICKSON, J
    KEMPF, D
    [J]. ARCHIVES OF VIROLOGY, 1994, : 19 - 29
  • [10] Structure-based design of protease inhibitors as therapeutics: Some examples.
    Reich, SH
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U595 - U595